Recruitment remains a well-known hurdle in Phase 1 oncology clinical trials, but what happens after enrolment is equally vital: patient retention. Keeping patients o...

Drug development commonly encounters a bottleneck at the clinical trial stage. Patient recruitment is notoriously challenging, with many studies facing costly delays...

Cancer prevalence is rising globally. Radiopharmaceuticals and Theranostics offer precise, targeted diagnostic and therapeutic solutions for safer, more tolerable on...

As the European and overall worldwide regulation strives to become clearer, unambiguous, harmonised and as a result, more restrictive and demanding, this tendency st...

The Asia-Pacific (APAC) region has rapidly emerged as one of the most dynamic markets in global clinical development. Over the past decade, demand for innovative the...

As artificial intelligence (AI) gains prominence in drug development, regulatory agencies such as the US Food and Drug Administration (FDA) are creating and implemen...

The UK biotech sector is thriving and with significant investment flowing into research, the opportunities for growth and innovation are considerable. In 2024, UK bi...

 Ahead of ARVO 2025 next week where Emmes is poised to launch the first dedicated ophthalmology clinical trial technology platform, we spoke with Saqib Parkar, ...

“All organisations, even the most renowned and successful, sometimes make the right things too hard and the wrong things too easy.”1 Sutton and Rao address this prob...

Europe’s regulatory environment is shifting fast. In the clinical trials space, recent years have brought sweeping changes, shaped by initiatives like the General Da...